5-fluorouracil + cisplatin + cyclophosphamide + docetaxel + epirubicin + trastuzumab

This drug is a combination chemotherapy regimen consisting of six agents used primarily in cancer treatment. It combines multiple mechanisms to attack cancer cells: - **5-Fluorouracil (5-FU)** is an antimetabolite that inhibits DNA synthesis by blocking thymidylate synthase, leading to cell death during DNA replication. - **Cisplatin** is an alkylating-like agent that forms DNA crosslinks, preventing DNA replication and transcription. - **Cyclophosphamide** is an alkylating agent that interferes with DNA replication by forming covalent bonds with DNA. - **Docetaxel** is a taxane that stabilizes microtubules and prevents their depolymerization, inhibiting mitosis. - **Epirubicin** is an anthracycline antibiotic similar to doxorubicin; it intercalates into DNA and inhibits topoisomerase II, causing breaks in the DNA strands. - **Trastuzumab** is a monoclonal antibody targeting the HER2 receptor (human epidermal growth factor receptor 2), blocking its signaling and inducing antibody-dependent cellular cytotoxicity. This combination leverages multiple cytotoxic mechanisms plus targeted therapy against HER2-positive cancers. It has been studied in various cancers including breast cancer and HER2-positive esophagogastric adenocarcinoma. Trastuzumab addition improves survival outcomes in HER2-positive tumors when combined with chemotherapy[6][8][10]. The regimen includes drugs from different classes such as alkylating agents, antimetabolites, taxanes, anthracyclines, and monoclonal antibodies.